Biocon

373.85
+4.50
(1.22%)
ann
There are 2 new updates from the company16 hours ago
Viewcross
right
Market Cap
49,982.39 Cr
EPS
8.46
PE Ratio
52.48
Dividend Yield
0.30 %
Industry
Healthcare
52 Week High
404.70
52 Week Low
291.00
PB Ratio
1.89
Debt to Equity
0.91
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+62.50 %
+62.50 %
Hold
Hold+18.75 %
+18.75 %
Sell
Sell+18.75 %
+18.75 %

Company News

View All News
Caret
neutral
Biocon to Review Q1 Results on August 715 hours ago
Biocon has announced that it will review its first quarter results on August 7. The company has scheduled a meeting to discuss and analyze its financial performance for the latest quarter.
positive
Biocon Biologics has obtained approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for two denosumab biosimilars, Vevzuo and Evfaxy. These biosimilars are versions of a medication used to treat various bone-related conditions.
positive
Biocon Biologics: EU Approves Two Denosumab Biosimilars5 days ago
Biocon Biologics, a subsidiary of Biocon Ltd., received European Commission marketing authorization for two Denosumab biosimilars, Vevzuo and Evfraxy. Vevzuo is for bone complications in advanced cancer, while Evfraxy treats osteoporosis in specific patient groups. This approval follows a positive CHMP opinion in April 2025.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,674.70
#1 4,01,816.63
35.03
#1 54,729.00
12.06
#1 10,980
-18.99
48.33
6,976.50
1,85,204.15
83.99
9,360.00
0.89
2,117
23.05
68.54
1,497.40
1,20,946.17
23.36
28,409.50
7.12
5,291
30.28
54.26
3,328.00
1,12,634.64
58.72
11,539.40
11.59
1,911
10.91
62.08
1,281.20
1,06,925.25
19.31
33,741.20
12.36
5,725
21.14
54.13
2,442.60
1,00,813.12
50.50
12,207.40
19.57
1,925
-10.91
59.65
976.70
98,278.87
21.18
22,573.80
13.82
3,977
-0.19
69.99
1,955.70
89,315.93
26.75
22,192.10
#1 19.94
3,024
#1 112.49
53.08
34,090.00
72,438.87
51.39
6,409.15
10.80
1,417
27.83
64.97
1,150.50
66,821.23
#1 19.29
31,378.10
17.55
3,366
-0.50
63.70

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
35.25 %
Net Income Growth
101.84 %
Cash Flow Change
59.45 %
ROE
79.37 %
ROCE
103.31 %
EBITDA Margin (Avg.)
6.64 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
952
778
800
811
1,223
1,029
989
1,086
974
986
1,025
1,098
1,242
1,193
1,564
1,585
1,557
1,483
1,673
1,784
1,621
1,712
1,765
1,885
2,060
1,808
1,945
2,223
2,476
2,217
2,384
3,020
3,929
3,516
3,551
4,135
3,912
4,543
3,604
3,826
4,415
Expenses
653
606
727
615
740
719
706
762
738
735
786
836
937
886
982
1,160
1,137
1,029
1,174
1,307
1,247
1,284
1,363
1,459
1,476
1,427
1,515
1,733
1,911
1,783
1,894
2,624
2,820
2,741
2,769
3,051
3,013
2,813
2,905
3,070
3,339
EBITDA
300
172
73
196
483
309
283
324
236
250
239
262
306
307
582
425
420
454
499
477
373
428
402
427
584
380
430
489
565
434
490
396
1,109
775
782
1,084
900
1,730
699
756
1,077
Operating Profit %
21 %
20 %
6 %
22 %
21 %
27 %
25 %
27 %
20 %
21 %
19 %
21 %
20 %
21 %
26 %
25 %
26 %
29 %
25 %
25 %
20 %
24 %
22 %
21 %
20 %
19 %
18 %
20 %
21 %
17 %
18 %
11 %
25 %
20 %
18 %
14 %
22 %
17 %
18 %
19 %
23 %
Depreciation
59
59
61
64
65
66
68
70
73
99
94
97
95
99
112
117
120
124
132
144
152
167
178
186
184
195
202
206
212
218
231
301
364
358
389
415
407
405
420
425
436
Interest
0
4
3
2
21
6
7
9
5
16
14
15
17
18
19
19
16
17
14
18
17
13
7
5
34
20
23
15
11
20
30
120
249
233
248
267
227
236
226
223
212
Profit Before Tax
249
165
20
141
409
238
208
245
159
135
132
150
193
190
451
289
284
313
354
315
204
249
218
236
366
166
206
269
343
197
229
-26
497
184
214
808
319
1,146
98
156
487
Tax
32
34
18
19
55
55
42
54
10
38
43
36
41
52
73
46
41
85
100
85
45
81
22
49
69
57
46
49
59
30
147
-5
82
35
42
55
96
284
71
75
27
Net Profit
217
131
2
122
354
182
167
191
148
98
89
114
153
138
378
243
243
228
254
230
159
168
195
187
296
108
160
220
284
167
82
-21
415
149
173
753
223
862
27
81
459
EPS in ₹
10.08
6.31
-0.54
5.30
16.97
8.49
7.48
8.72
6.49
1.38
1.17
1.56
2.21
1.02
3.00
3.67
3.61
1.74
1.82
1.71
1.04
1.26
1.39
1.42
2.13
0.71
1.16
1.57
2.00
1.21
0.39
-0.35
2.62
0.85
1.05
5.52
1.13
5.51
-0.13
0.21
2.88

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
6,375
8,458
9,394
9,990
12,192
14,444
18,522
20,394
52,043
56,071
58,797
Fixed Assets
1,630
1,749
3,626
3,700
4,471
5,971
6,364
6,569
29,468
30,644
23,686
Current Assets
2,563
3,971
4,048
4,149
4,889
5,325
7,600
8,382
12,334
15,179
16,286
Capital Work in Progress
1,677
2,240
839
1,303
1,899
2,196
2,800
4,110
7,317
7,993
4,102
Investments
230
901
1,253
675
1,012
966
1,952
1,588
2,069
1,000
4,931
Other Assets
2,839
3,569
3,676
4,312
4,811
5,311
7,406
8,127
13,189
16,434
0
Total Liabilities
6,375
8,458
9,394
9,990
12,192
14,444
18,522
20,394
52,043
56,071
58,797
Current Liabilities
1,555
1,666
1,678
2,141
3,039
4,008
4,210
3,828
8,511
15,359
14,334
Non Current Liabilities
1,378
2,493
2,502
2,200
2,447
3,053
5,805
7,096
21,043
15,437
16,751
Total Equity
3,443
4,300
5,214
5,649
6,707
7,383
8,508
9,470
22,489
25,275
21,644
Reserve & Surplus
3,171
3,992
4,738
4,881
5,798
6,106
7,027
7,832
17,267
19,183
21,044
Share Capital
100
100
100
300
300
600
600
600
600
600
600

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-94
300
-47
-261
210
165
72
-243
641
-380
Investing Activities
-491
-1,138
-510
-684
-703
-1,505
-3,651
-1,662
-14,260
-1,002
Operating Activities
211
371
640
662
1,155
1,283
1,160
1,177
1,853
2,954
Financing Activities
186
1,068
-178
-240
-242
388
2,564
242
13,049
-2,333

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
60.67 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
54.45 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
7.96 %
6.55 %
5.63 %
5.90 %
5.93 %
5.66 %
5.66 %
7.00 %
DIIs
6.65 %
6.89 %
6.87 %
6.83 %
7.79 %
7.30 %
7.76 %
8.63 %
11.90 %
12.56 %
14.08 %
14.51 %
13.68 %
14.30 %
14.44 %
15.37 %
15.72 %
21.45 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
10.89 %
11.03 %
11.49 %
11.37 %
10.87 %
10.72 %
12.07 %
12.46 %
13.21 %
13.34 %
13.61 %
14.47 %
15.53 %
14.63 %
14.57 %
14.07 %
13.63 %
13.08 %
Others
21.79 %
21.44 %
21.00 %
21.16 %
20.70 %
21.35 %
19.54 %
18.27 %
14.26 %
13.46 %
3.70 %
3.83 %
4.52 %
4.53 %
4.42 %
4.27 %
4.34 %
4.00 %
No of Share Holders
0
3,11,349
3,38,815
3,63,447
3,64,502
3,47,911
3,41,016
3,69,816
4,11,086
4,12,441
4,15,046
4,34,339
4,70,261
4,43,513
4,39,503
4,27,705
4,24,297
4,30,217

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 1 1 0.00 0.00 0.5 1.5 0.5 0.00
Dividend Yield (%) 0.00 1.01 0.33 0.37 0.00 0.00 0.25 0.57 0.15 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
08 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
08 Aug 2025 334.60 369.35
04 Jul 2025 DIVIDEND Dividend
₹ 0.50 /share
04 Jul 2025 334.60 380.05
08 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 May 2025 342.25 334.60
30 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Jan 2025 369.25 357.15
30 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Oct 2024 356.95 320.70
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 305.90 336.95
05 Jul 2024 DIVIDEND Dividend
₹ 0.50 /share
05 Jul 2024 305.90 370.20
07 Jul 2023 DIVIDEND Dividend
₹ 1.50 /share
07 Jul 2023 242.25 254.00
01 Jul 2022 DIVIDEND Dividend
₹ 0.50 /share
30 Jun 2022 376.75 311.65
13 Jun 2019 BONUS Bonus
1:1
12 Jun 2019 270.50 256.40

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation16 hours ago
Board Meeting Intimation for Board Meeting Intimation To Approve And Take On Record The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 202516 hours ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication4 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release9 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 27, 2025
Closure of Trading WindowJun 26, 2025
Disclosure Under Regulation 30 Of The SEBI Listing RegulationsJun 26, 2025
Board Meeting Outcome for Outcome Of Board MeetingJun 26, 2025
Communication To The Shareholders W.R.T. TDS On Final DividendJun 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 20, 2025
Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJun 20, 2025
Qualified Institutions Placement - Approval And Adoption Of The Placement Document Dated June 19 2025Jun 19, 2025
Qualified Institutions PlacementJun 19, 2025
Credit RatingJun 18, 2025
Qualified Institutions Placement Of Equity SharesJun 16, 2025
Intimation Of The Approval Of The Audited Consolidated Financial Statements For The Financial Year March 31 2025Jun 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 09, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 04, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 04, 2025
Press ReleaseJun 02, 2025
Reminder Letter To Holders Of Physical Securities For Furnishing Of KYC DetailsMay 27, 2025
Company StatementMay 25, 2025
Company StatementMay 22, 2025
Company StatementMay 21, 2025
Transcript Of Earnings Call Q4 FY25May 15, 2025
Notification To Stock ExchangeMay 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
Reminder Letter To Shareholders To Claim Unclaimed DividendsMay 13, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 12, 2025
Investor PresentationMay 12, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 09, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 09, 2025
Fixation Of Record Date For DividendMay 08, 2025
Corporate Action-Board approves DividendMay 08, 2025
Board Meeting Outcome for Financial Results For Quarter And Year Ended March 31 2025May 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 08, 2025
Financial Results For The Quarter And Year Ended March 31 2025May 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 06, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 05, 2025
Intimation Of Record Date For Commercial PapersApr 30, 2025
Redemption Of Commercial PapersApr 29, 2025
Company Statement Dated April 26 2025Apr 26, 2025
Board Meeting Outcome for Outcome Of Board MeetingApr 23, 2025
Issue Of Commercial PapersApr 22, 2025
Board Meeting Intimation for To Consider And Approve The Proposal For Raising Of Funds.Apr 20, 2025

Technical Indicators

RSI(14)
Neutral
62.43
ATR(14)
Less Volatile
9.09
STOCH(9,6)
Overbought
85.08
STOCH RSI(14)
Neutral
65.80
MACD(12,26)
Bullish
1.66
ADX(14)
Strong Trend
26.31
UO(9)
Bearish
61.95
ROC(12)
Uptrend And Accelerating
5.12
WillR(14)
Neutral
-32.44

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
SBI Contra Direct Plan-Growth
0.00%
-19520774
-1.44%
-1.43%
Kotak Large & Midcap Fund Direct-Growth
0.00%
-13000000
-1.61%
-1.63%
SBI Balanced Advantage Fund Direct - Growth
0.00%
-10021205
-0.95%
-0.92%
SBI Mid Cap Direct Plan-Growth
0.00%
-7000000
-1.05%
-1.05%
Nippon India Focused Fund Direct-Growth
0.00%
-6715683
-2.64%
-2.64%
HSBC Midcap Fund Direct-Growth
0.00%
-4080000
-1.19%
-1.22%
Mirae Asset Large Cap Fund Direct- Growth
0.00%
-2841525
-0.24%
-0.24%
ICICI Prudential Multi Asset Fund Direct-Growth
0.00%
-2675000
-0.15%
-0.15%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.00%
-2652542
-1.62%
-1.61%
Kotak Arbitrage Fund Direct-Growth
0.00%
-2505000
-0.12%
-0.08%
Nippon India ELSS Tax Saver Fund Direct-Growth
0.00%
-2401231
-0.53%
-0.52%
Nippon India Pharma Fund Direct-Growth
0.00%
-2284222
-0.92%
-0.89%
Nippon India Vision Large & Mid Cap Direct-Growth
0.00%
-2083678
-1.19%
-1.17%
SBI Healthcare Opportunities Fund Direct Plan-Growth
0.00%
-2000000
-1.82%
-1.75%
SBI Multi Asset Allocation Fund Direct-Growth
0.00%
-1916589
-0.77%
-0.77%
Bandhan Large & Mid Cap Fund Direct-Growth
0.00%
-1724461
-0.64%
-0.66%
Kotak Manufacture in India Fund Direct - Growth
0.00%
-1600000
-2.21%
-2.24%
Mahindra Manulife Mid Cap Fund Direct - Growth
0.00%
-1310000
-1.17%
-1.19%
Mahindra Manulife Focused Fund Direct - Growth
0.00%
-1295000
-2.06%
-2.02%
Invesco India Arbitrage Fund Direct-Growth
0.00%
-1182500
-0.18%
0.00%
Mirae Asset Multicap Fund Direct - Growth
0.00%
-1150000
-1.04%
-1.06%
Nippon India Balanced Advantage Fund Direct-Growth
0.00%
-1124999
-0.41%
-0.40%
HDFC Large and Mid Cap Fund Direct- Growth
0.00%
-1000000
-0.13%
-0.13%
Mirae Asset Healthcare Fund Direct - Growth
0.00%
-963919
-1.20%
-1.16%
ICICI Prudential Equity Arbitrage Direct-Growth
0.00%
-872500
-0.10%
-0.08%

About Biocon

Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years, 2 days)
Chairperson NameKiran Mazumdar Shaw